Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsNr munjal

    Nr Munjal

    Jump to

    • Ind Swift Labs gets USFDA nod for two more DMFs

      Pharma major Ind-Swift Laboratories Ltd, which has a strong basket of over 40 products across 16 therapeutic segments, has got the USFDA nod for two more DMFs Temozolomide and Telmisartan. Besides commercially supplying four molecules to the US, the company has hitherto filed 20 DMFs with the USFDA, of which all have been approved.

    • How Indian pharma SMEs can capture the global market

      CNBC-TV18 special series for small and medium enterprises 'SME CEO Knowledge Series' discusses the strengths of the SME sector and the opportunities available to them to get them to a global stage.

    • Pharma firms want tax cuts, R&D sops boost

      Drugmakers want tax exemption deadline for export oriented unit (EOUs) to be extended and want infrastructure or priority sector status in the budget on Feb 28.

    • India drug transport cost may fall 15%-20% if dispute ends

      The transportation costs of Indian drug firms is expected to fall by 15% to 20% percent once a dispute between India and Europe over drug shipments is resolved, NR Munjal, president, Indian Drug Manufacturers' Association, told Reuters.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347